One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Soligenix, Inc.
SNGX · NCM · Healthcare · Biotechnology
Current price
$0.33
52-week range
$0.28 - $1.70
Market cap
$7.75M
Balance sheet
Healthy
-55.36x Concerning
Net cash $8.75M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
Soligenix, Inc.
Soligenix sells treatments for rare diseases, mainly developing new medicines like SGX301 for a skin condition and vaccines for public health threats. Their money primarily comes from research grants and potential future sales of these specialized medical products, which is important because it shows they are working on life-changing treatments in areas with fewer existing options.
What it actually does
Soligenix is a biopharmaceutical company dedicated to creating and selling treatments for rare diseases, which are conditions that affect a small number of people. They focus on areas where there aren't many good treatment options available. The company works on developing new drugs and vaccines, often for conditions that are difficult to treat or have limited existing therapies. Their work involves extensive research, clinical trials (testing in people), and seeking regulatory approval to make these treatments available to patients who need them.
Specialized BioTherapeutics
This part of Soligenix focuses on developing treatments for rare diseases, particularly in areas like oncology (cancer) and inflammatory conditions. One key product is HyBryte™ (SGX301), a photodynamic therapy for cutaneous T-cell lymphoma (CTCL), a rare skin cancer. They are also developing SGX302 for psoriasis and SGX945 (dusquetide) for Behçet's disease, an autoimmune condition causing painful ulcers. These therapies aim to offer new options for patients with specific, often chronic, conditions where current treatments may have significant side effects or limited effectiveness.
Public Health Solutions
This segment of Soligenix is geared towards developing medical countermeasures for public health threats, often supported by government funding. A major focus is RiVax®, a vaccine candidate designed to protect against ricin toxin poisoning. They are also working on vaccine programs for viral diseases like Ebola and Marburg, as well as emerging infectious diseases. A key technology here is ThermoVax®, which helps stabilize vaccines, making them easier to store and transport without needing refrigeration. This segment addresses critical needs in biodefense and infectious disease preparedness.
What management is betting on now
Soligenix's management is focused on advancing its pipeline of rare disease treatments and public health solutions. A key priority is the development of HyBryte™ for CTCL, despite recent study outcomes, with ongoing data analysis to understand its potential. They are also advancing SGX945 for Behçet's disease, which has received important designations from regulatory agencies. The company continues to leverage its ThermoVax® technology for vaccine development, often supported by government grants. Management's strategy involves a de-risked development model, focusing on orphan diseases and utilizing non-dilutive funding to manage costs and extend their financial runway.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2025 Q2
$-2.75M
FY2025 Q3
$-2.93M
FY2025 Q4
$-2.75M
Revenue
—
Net income
$-1.12M
Diluted EPS
-0.05
Operating cash flow
$-1.42M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-1.99M
Diluted EPS
-0.12
Operating cash flow
$-1.71M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-2.82M
Diluted EPS
-0.28
Operating cash flow
$-2.36M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-2.61M
Diluted EPS
0.32
Operating cash flow
$-2.75M
Free cash flow
$-2.75M
Fetching…
Sources
Revenue
—
Net income
$-2.53M
Diluted EPS
-0.58
Operating cash flow
$-2.93M
Free cash flow
$-2.93M
Fetching…
Sources
Revenue
—
Net income
$-2.70M
Diluted EPS
-0.82
Operating cash flow
$-2.74M
Free cash flow
$-2.75M
Fetching…
Sources
Revenue
—
Net income
$-3.24M
Diluted EPS
-1.06
Operating cash flow
$-1.85M
Free cash flow
—
Fetching…
Sources
Revenue
$-2.34K
Net income
$-2.99M
Diluted EPS
-2.71
Operating cash flow
$-2.23M
Free cash flow
—
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $0.33
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $8.7M - more cash than debt. Interest coverage -55.4x.
Net debt
$-8.75M
Interest coverage
-55.36x
Soligenix, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 3 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
SNGX
BASELINE
Soligenix, Inc.
Total debt $273.92K Interest coverage -55.36x This is the baseline the peer rows are being compared against.
Total debt $19.87M Interest coverage -23.92x Neither company has much profit cushion over interest right now.
Total debt $205.66K Interest coverage -5.59x Neither company has much profit cushion over interest right now.
Total debt $36.02M Interest coverage -57.76x Neither company has much profit cushion over interest right now.
What you should know
The case for and against SNGX
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -127.4% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-1.33x
P/B
1.24x
P/S
—
EV/EBITDA
0.08x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-127.4%
ROA
-59.2%
Health
Liquidity and balance-sheet strength
Debt / equity
0.04x
Current ratio
3.00x
Quick ratio
2.95x
Total debt
$273.92K
Total cash
$9.02M
Growth
How the business has been compounding
Revenue TTM
$119.37K
Revenue 5Y CAGR
-38.3%
EPS TTM
-0.79
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-8.23M
Free CF TTM
$-10.27M
FCF margin
-8,605.5%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—